RAPT Therapeutics (NASDAQ: RAPT) shot up in value by 90% this week.
This article shines a light on the value proposition presented by RAPT Therapeutics. Scroll through this page to discover what the company is, what it does, whether or not you should buy shares right now, and the best places to buy RAPT stock online.
How and where to buy RAPT Therapeutics stock
The best place to buy RAPT shares is a reliable online stockbroker. These are low-fee platforms that offer investors easy access to hundreds of trading instruments, from stocks and forex to commodities and cryptocurrencies.
Our top two picks for investing in RAPT Therapeutics shares are listed below:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is RAPT Therapeutics?
It is a clinical-stage immunology-based biopharmaceutical company. The company’s central focus is on discovering, developing, and commercialising oral small molecule therapies for patients with needs in oncology and inflammatory diseases that have previously been unmet.
Why is RAPT stock rising in value?
RAPT’s top-line results from an early-stage study of RPT193 – a drug designed to treat moderate-to-severe atopic dermatitis – were strong.
Should I buy RAPT stock today?
If you buy into the strength of the company’s management team and their ability to monetise the many potential treatments they are currently working on, now could be a good time to buy ahead of future growth.
However, make sure you recognise the inherent risks when investing in a pharmaceutical company. These companies have to progress treatments through the length and rigorous testing process of the medical authorities, and there are plenty of opportunities for things to go wrong along the way.
All in all, RAPT is definitely a solid stock to consider right now, especially if it can progress RPT193 into a commercially viable treatment.